Novartis AG ADR (NVS)vsScienture Holdings, Inc. (SCNX)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
SCNX
Scienture Holdings, Inc.
$0.35
-2.69%
HEALTHCARE · Cap: $15.32M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6902569% more annual revenue ($56.69B vs $821,320). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SCNX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+61.0%
Fair Value
$1.15
Current Price
$0.35
$0.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 449.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -0.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX carries more volatility with a beta of 3.98 — expect wider price swings.
SCNX is growing revenue faster at 449.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. SCNX offers better value entry with a 61.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?